Evidence map›Paper›PMID 26370509›Full record

ReviewMolecular and cellular biology2015

The New State of the Art: Cas9 for Gene Activation and Repression.

Marie F La Russa, Lei S Qi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular and cellular biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

113 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. From Lab to Field: CRISPRing Major CultivatedInternational journal of molecular sciences · 2026
    Review
  3. EditingBiomolecules · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. CRISPR Technology and Its Emerging Applications.Genomics, proteomics & bioinformatics · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

53 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Marie F La RussaBiomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, California, USA Department of Bioengineering, Stanford University, Stanford, California, USA.
Lei S QiDepartment of Bioengineering, Stanford University, Stanford, California, USA Department of Chemical and Systems Biology, Stanford University, Stanford, California, USA Stanford ChEM-H (Chemistry, Engineering & Medicine for Human Health), Stanford University, Stanford, California, USA stanley.qi@stanford.edu.

Funding

PREDOCTORAL TRAINING IN BIOMEDICAL SCIENCEST32GM008568 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANSEL, KARL MARK · 1995 to 2019
$6.3M
Harnessing CRISPR for Targeted and Inducible Epigenomic ReprogrammingR01DA036858 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIM, WENDELL A, QI, LEI STANLEY · 2013 to 2017
$2.9M
A novel RNA-guided platform for sequence-specific cell reprogrammingDP5OD017887 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI QI, LEI STANLEY · 2013 to 2017
$2.0M
NIDA NIH HHS R01 DA036858NIGMS NIH HHS T32 GM008568NIH HHS DP5 OD017887
6 · The paper itself

Abstract

CRISPR-Cas9 technology has rapidly changed the landscape for how biologists and bioengineers study and manipulate the genome. Derived from the bacterial adaptive immune system, CRISPR-Cas9 has been coopted and repurposed for a variety of new functions, including the activation or repression of gene expression (termed CRISPRa or CRISPRi, respectively). This represents an exciting alternative to previously used repression or activation technologies such as RNA interference (RNAi) or the use of gene overexpression vectors. We have only just begun exploring the possibilities that CRISPR technology offers for gene regulation and the control of cell identity and behavior. In this review, we describe the recent advances of CRISPR-Cas9 technology for gene regulation and outline advantages and disadvantages of CRISPRa and CRISPRi (CRISPRa/i) relative to alternative technologies.

Indexed as

CRISPR-Cas SystemsGene Expression RegulationAnimalsBacteriaClustered Regularly Interspaced Short Palindromic RepeatsGenetic EngineeringHumans

Identifiers

PMID26370509
PMCPMC4609748

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.